Table 1.
Chromatographic data of chiral illicit drugs and controlled substances separated on the LARIHC CF6-P and LARIHC CF7-DMP columns in the optimized conditions.
| Drug | Structure | CSP | Mobile Phase | rt1/min | rt2/min | α | Rs | |
|---|---|---|---|---|---|---|---|---|
| (1) | Lysergic acid diethylamide (6aR,9R/6aS,9S)-9,10-Didehydro-N,N-diethyl-6-methylergoline-8β-carboxamide |
|
LARIHC CF6-P | 90ACN/10MeOH/0.3AA/0.2TEA | 59.1 | 67.5 | 1.15 | 2.5 |
| (2) | Stanozolol (1S,3aS,3bR,5aS,10aS,10bS,12aS/1 R,3aR,3bS,5aR,10aR10bR,12aR)- 5α,17β-17-Methyl-2'H-androst-2-eno[3,2-c]pyrazol- 17-ol |
|
LARIHC CF6-P | 80HEP/20EtOH/0.1TFA | 24.0 | 34.7 | 1.51 | 2.0 |
| (3) | Cathinone HCl (R/S)-2-Amino-1 -phenyl-1 -propanone hydrochloride |
|
LARIHC CF6-P | 70HEP/30EtOH/0.1TFA | 50.7 | 55.0 | 1.09 | 1.5 |
| (4) | (R/S)-3,4-Methylenedioxyphenyl-2-butanamine hydrochloride |
|
LARIHC CF6-P | 60ACN/40MeOH/0.3AA/0.2TEA | 9.9 | 10.5 | 1.08 | 1.5 |
| (5) | Phenylpropanolamine (1R,2S/1S,2R)-α-Hydroxy-β- aminopropylbenzene hydrochloride |
|
LARIHC CF6-P | 60ACN/40MeOH/0.3AA/0.2TEA | 13.8 | 15.0 | 1.08 | 1.5 |
| (6) | Methadone (R/S)-6-Dimethylamino-4,4- diphenyl-3 -heptanone |
|
LARIHC CF6-P | 85ACN/15MeOH/0.3AA/0.2TEA | 16.5 | 18.2 | 1.13 | 1.3 |
| (7) | MDA (R/S)-3,4- Methylenedioxyamphetamine |
|
LARIHC CF6-P | 80ACN/20MeOH/0.3AA/0.2TEA | 46.5 | 48.7 | 1.05 | 1.3 |
| (8) | Venlafaxine (R/S)- 1-[2-(dimethylamino)-1 -(4- methoxyphenyl)ethyl]cyclohexanol hydrochloride |
|
LARIHC CF6-P | 80ACN/20MeOH/0.3AA/0.2TEA | 9.6 | 9.9 | 1.05 | 1.0 |
| (9) | (R/S)-p-Methoxyamphetamine hydrochloride |
|
LARIHC CF6-P | 80ACN/20MeOH/0.3AA/0.2TEA | 45.6 | 47.7 | 1.02 | 0.8 |
| (10) | Aminorex (R/S)-4,5-Dihydro-5-phenyl-2- oxazolamine |
|
LARIHC CF6-P | 80ACN/20MeOH/0.3AA/0.2TEA | 13.8 | 14.1 | 1.03 | 0.6 |
| (11) | Amphetamine (R/S)-1-Phenyl-2- aminopropane |
|
LARIHC CF6-P | 80ACN/20MeOH/0.3AA/0.2TEA | 44.1 | 44.5 | 1.01 | 0.4 |
| (12) | Hydrocodone (5R,9R,13S,14R/6R,9S,13R14 S)-4,5-Epoxy-3 -methoxy-17- methylmorphinan-6-one |
|
LARIHC CF6-P | 80ACN/20MeOH/0.3AA/0.2TEA | 11.1 | 11.3 | 1.03 | 0.5 |
| (13) | (R/S)-Clenbuterol |
|
LARIHC CF7- DMP | 80Hep/20EtOH/0.1TFA | 12.9 | 14.8 | 1.19 | 2.0 |
| (14) | Temazepam (R/S)-7-Chloro-1,3-dihydro-3-hyd roxy-1 -methyl-5-phenyl-2H-1,4- benzodiazepine-2-one |
|
LARIHC CF7- DMP | 80Hep/20EtOH/0.1TFA | 13.5 | 14.6 | 1.10 | 1.8 |
*Marks a stereogenic center. For the possible enantiomeric configurations about these centers, refer to the description in the drug name column.